Again, I wonder how useful this really is for most applicants. First thing you notice is that it takes a perfect score to get funded. Three of the four received 10s and the fourth limped home with an 11. Remember, the study section score range starts at 1, which is then multiplied by 10 after the voting of the entire panel is averaged.
Then there's this (emphasis added):
From the Dow summary statement's resume of discussion: "Strengths of the application include the accomplished investigator and research team, strong preliminary data, the direct doable and logical set of experiments, and the likelihood of paradigm shifting insights into meliodosis"
From the resume on the Starnbach app: "Strengths of the application include the innovative use of the novel GPS strategy, compelling preliminary data, an investigator with a strong bacterial pathogenesis research track record, an excellent and appropriate set of collaborators, and a high degree of confidence that import results will emerge from these studies."
Weis, individual critique #2: "Strong and compelling preliminary data is presented that indicate a high likelihood of success"
Well, at least NIAID is telling it like it is with these examples.....